keyword
Keywords lung activity disease systemic...

lung activity disease systemic sclerosis

https://read.qxmd.com/read/37934671/-characteristics-of-patients-with-systemic-sclerosis-who-develop-interstitial-lung-disease
#21
JOURNAL ARTICLE
Luis Daniel Fajardo-Hermosillo, Mario César Ocampo-Torres, Juan Rodríguez-Silverio
BACKGROUND: Systemic sclerosis associated-interstitial lung disease (SSc-ILD) show a high mortality. The factors associated SSc-ILD have shown variability in different populations. There are few studies in Mexican mestizos. OBJECTIVE: To analyze the epidemiological, clinical and paraclinical factors associated with SSc-ILD. MATERIAL AND METHODS: Cross-sectional study, where patients > 18 years of age with a diagnosis of SSc according to EULAR/ACR 2013 criteria and diagnosis of ILD by forced vital capacity (FVC) < 70% and > 5% of affected lung area on tomography were included...
October 2, 2023: Revista Médica del Instituto Mexicano del Seguro Social
https://read.qxmd.com/read/37927735/pulmonary-cavitary-sarcoidosis-a-case-report
#22
Bhanu Shrestha, Ravi Mahat
Sarcoidosis is a granulomatous disease characterized by a non-caseating granuloma formation in different organs of the body. However, the presence of cavitary lesions is rare. We present a case report of a 38-year-old male who presented with a three-month history of cough, dyspnea, and weight loss. Computed tomography of the chest demonstrated enlarged mediastinal and bilateral hilar lymphadenopathy with bilateral perihilar consolidation and cavitation in the upper lobes of both lungs. Later, the patient underwent bronchoscopy with bronchoalveolar lavage and endobronchial biopsy which showed well-formed and non-necrotizing granulomas which were also embedded in the dense hyaline sclerosis...
October 2023: Curēus
https://read.qxmd.com/read/37886934/biomarkers-in-systemic-sclerosis-an-overview
#23
REVIEW
Giuseppe Di Maggio, Paola Confalonieri, Francesco Salton, Liliana Trotta, Luca Ruggero, Metka Kodric, Pietro Geri, Michael Hughes, Mattia Bellan, Michele Gilio, Selene Lerda, Elisa Baratella, Marco Confalonieri, Lucrezia Mondini, Barbara Ruaro
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by significant fibrosis of the skin and internal organs, with the main involvement of the lungs, kidneys, heart, esophagus, and intestines. SSc is also characterized by macro- and microvascular damage with reduced peripheral blood perfusion. Several studies have reported more than 240 pathways and numerous dysregulation proteins, giving insight into how the field of biomarkers in SSc is still extremely complex and evolving. Antinuclear antibodies (ANA) are present in more than 90% of SSc patients, and anti-centromere and anti-topoisomerase I antibodies are considered classic biomarkers with precise clinical features...
September 25, 2023: Current Issues in Molecular Biology
https://read.qxmd.com/read/37884942/acsl4-inhibition-prevents-macrophage-ferroptosis-and-alleviates-fibrosis-in-bleomycin-induced-systemic-sclerosis-model
#24
JOURNAL ARTICLE
Dianyu Cao, Jina Zheng, Zheng Li, Yong Yu, Zengrui Chen, Qiang Wang
BACKGROUND: Systemic sclerosis (SSc), with unclear pathophysiology, is a paradigmatic rheumatic disease of immunity dysfunction-driven multi-organ inflammation and ultimate fibrosis. Pathogenesis breakthroughs are urgently needed for available treatments halting its unremitting stiffness. This study aims to investigate whether ferroptosis can regulate the progressive SSc fibrosis. METHODS: In vivo, bleomycin (BLM)-induced mice model was subjected to ferroptosis detection using western blotting, malondialdehyde (MDA), and glutathione (GSH) assays...
October 26, 2023: Arthritis Research & Therapy
https://read.qxmd.com/read/37833608/anti-topoisomerase-1-antibody-level-changes-after-b-cell-depletion-therapy-in-systemic-sclerosis
#25
JOURNAL ARTICLE
L P Ananyeva, L A Garzanova, O A Koneva, M N Starovoytova, O V Desinova, O B Ovsyannikova, R U Shayakhmetova, M V Cherkasova, A P Aleksankin, E L Nasonov
The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANAs) and autoantibodies to topoisomerase 1 (anti-Topo 1) in systemic sclerosis (SSs) patients on rituximab (RTX) therapy. The prospective study included 88 patients (73 women) with a mean age of 47 (17-71) years. The mean disease duration was 5.9 ± 4.8 years. The mean follow-up period was more than 2 years (27 (12-42) months). We documented a statistically significant change in skin score, the disease activity index, improvement of pulmonary function and reduction of mean dose of prednisolone after RTX treatment...
August 2023: Doklady. Biochemistry and Biophysics
https://read.qxmd.com/read/37831911/does-reduced-cathepsin-activity-contribute-to-skin-and-lung-fibrosis-in-patients-with-systemic-sclerosis-and-related-disorders
#26
JOURNAL ARTICLE
Mark Garton, Clive Kelly
No abstract text is available yet for this article.
October 13, 2023: Rheumatology
https://read.qxmd.com/read/37796708/potential-therapeutic-targets-of-resveratrol-in-the-prevention-and-treatment-of-pulmonary-fibrosis
#27
REVIEW
Iman Ramli, Thamere Cheriet, Anna Maria Posadino, Roberta Giordo, Hatem Zayed, Ali H Eid, Gianfranco Pintus
Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer...
September 14, 2023: Frontiers in Bioscience (Landmark Edition)
https://read.qxmd.com/read/37777970/prognostic-value-of-right-atrial-strain-in-systemic-sclerosis-based-on-tissue-tracking-analysis-using-cine-cardiac-magnetic-resonance-imaging-a-retrospective-observational-study
#28
JOURNAL ARTICLE
Akiko Sakai, Michinobu Nagao, Atsushi Yamamoto, Risako Nakao, Shuji Sakai, Junichi Yamaguchi
Interstitial lung disease and cardiac involvement are common manifestations and prognostic factors of systemic sclerosis. However, it is unclear whether impaired right atrial function associated with interstitial lung disease in systemic sclerosis can be used as a prognostic factor in this patient population. Therefore, this study aimed to investigate the relationship between right atrial function, interstitial lung disease, and prognosis in patients with systemic sclerosis using tissue tracking analysis with cine cardiac magnetic resonance imaging...
October 1, 2023: Heart and Vessels
https://read.qxmd.com/read/37753072/proteomic-aptamer-analysis-reveals-serum-biomarkers-associated-with-disease-mechanisms-and-phenotypes-of-systemic-sclerosis
#29
JOURNAL ARTICLE
Francesca Motta, Antonio Tonutti, Natasa Isailovic, Angela Ceribelli, Giovanni Costanzo, Stefano Rodolfi, Carlo Selmi, Maria De Santis
BACKGROUND: Systemic sclerosis (SSc) is an autoimmune connective tissue disease that affects multiple organs, leading to elevated morbidity and mortality with limited treatment options. The early detection of organ involvement is challenging as there is currently no serum marker available to predict the progression of SSc. The aptamer technology proteomic analysis holds the potential to correlate SSc manifestations with serum proteins up to femtomolar concentrations. METHODS: This is a two-tier study of serum samples from women with SSc (including patients with interstitial lung disease - ILD - at high-resolution CT scan) and age-matched healthy controls (HC) that were first analyzed with aptamer-based proteomic analysis for over 1300 proteins...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37745675/sex-differences-in-clinical-outcomes-and-biological-profiles-in-systemic-sclerosis-associated-interstitial-lung-disease-a-post-hoc-analysis-of-two-randomised-controlled-trials
#30
JOURNAL ARTICLE
Elizabeth R Volkmann, Donald P Tashkin, Richard Silver, Carol Feghali Bostwick, Shervin Assassi, DeAnna Baker Frost, Mei Leng, Holly Wilhalme, Grace Hyun Kim, Jonathan Goldin, Michael D Roth
BACKGROUND: Observational studies have shown that men with systemic sclerosis have an increased risk of interstitial lung disease (ILD) and mortality compared with women. However, previous studies have not controlled for treatment effect or evaluated the biological mechanism or mechanisms underlying this sex difference. We aimed to compare ILD progression and long-term morbidity and mortality outcomes in male and female participants of two randomised controlled trials for systemic sclerosis-associated ILD...
October 2022: Lancet Rheumatology
https://read.qxmd.com/read/37700377/arsenic-trioxide-demonstrates-efficacy-in-a-mouse-model-of-preclinical-systemic-sclerosis
#31
JOURNAL ARTICLE
Anne Cauvet, Arthur Decellas, Christophe Guignabert, Dominique Rongvaux-Gaïda, Raphaël Thuillet, Mina Ottaviani, Ly Tu, François Rieger, Jérôme Avouac, Yannick Allanore
BACKGROUND: Uncontrolled T-cell activation plays a key role in systemic sclerosis (SSc). Arsenic trioxide (ATO) has immunological effects and has demonstrated potential in preclinical SSc models. In this study, we assessed the efficacy of ATO in Fra2 transgenic (Fra2TG ) mice, which develop severe vascular remodeling of pulmonary arterioles and nonspecific interstitial pneumonia-like lung disease, closely resembling human SSc-associated pulmonary hypertension, therefore partially resembling to the SSc human disease...
September 12, 2023: Arthritis Research & Therapy
https://read.qxmd.com/read/37680510/proprotein-convertase-subtilisin-kexin-9-pcsk9-in-patients-with-diffuse-systemic-sclerosis-a-marker-of-disease-activity-and-severe-disease-manifestations-with-potential-therapeutic-implementations
#32
JOURNAL ARTICLE
Joy Artin, Yumn A Elsabagh, Laila Rashed, Mohamed A Hussein
OBJECTIVES: This study aims to investigate proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis (d-SSc) and its relation to disease activity, severity and subclinical atherosclerosis in such group of patients. PATIENTS AND METHODS: Between December 2019 and July 2021, a total of 41 patients with d-SSc (17 males, 24 females; mean age: 36.1±1.9 years; range, 19 to 58 years) and 41- age and sex-matched healthy controls (17 males, 24 females; mean age: 40...
June 2023: Archives of Rheumatology
https://read.qxmd.com/read/37670355/serum-interleukin-6-level-and-its-association-with-pulmonary-involvement-in-progressive-systemic-sclerosis-a-case-control-study
#33
JOURNAL ARTICLE
Ahmad Piroozmand, Batool Zamani, Hamed Haddad Kashani, Javad Amini Mahabadi
BACKGROUND: Primary Systemic Sclerosis (PSS) is a connective tissue disorder characterized by excessive collagen deposition in the skin and internal organs. Interstitial lung disease (ILD) is a late demonstration of PSS and cytokines can contribute to the disease pathology. The purpose of the current study was to determine the association between serum interleukin-6 level and pulmonary involvement in progressive systemic sclerosis. METHODS AND MATERIALS: Demographic data and serum interleukin-6 levels were measured for 30 PSS patients with pulmonary involvement (case group) and 30 PSS patients without pulmonary involvement (control group) following informed consent...
September 5, 2023: Clinical and Molecular Allergy: CMA
https://read.qxmd.com/read/37650691/emerging-cellular-and-immunotherapies-for-systemic-sclerosis-from-mesenchymal-stromal-cells-to-car-t-cells-and-vaccine-based-approaches
#34
JOURNAL ARTICLE
Alain Lescoat, Hiroshi Kato, John Varga
PURPOSE OF REVIEW: Although two targeted therapies have received recent approval for systemic sclerosis (SSc)-associated interstitial lung disease, they do not show major disease-modifying activity, highlighting the need for novel therapies and innovative paradigms. To that end, cellular therapies may represent a new opportunity for the treatment of SSc. The purpose of this review is to provide an up-to-date overview of emerging cell-based disease-modifying therapies in SSc. RECENT FINDINGS: Initial small studies in patients with severe refractory systemic lupus erythematosus (SLE) using engineered regulatory cells show promising results...
November 1, 2023: Current Opinion in Rheumatology
https://read.qxmd.com/read/37626391/a-cysteine-proteinase-inhibitor-alln-alleviates-bleomycin-induced-skin-and-lung-fibrosis
#35
JOURNAL ARTICLE
Hiroshi Kasamatsu, Takenao Chino, Takumi Hasegawa, Natsuko Utsunomiya, Akira Utsunomiya, Masami Yamada, Noritaka Oyama, Minoru Hasegawa
BACKGROUND: Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis in the skin and internal organs, such as the lungs. Activated differentiation of progenitor cells, which are mainly resident fibroblasts, into myofibroblasts is considered a key mechanism underlying the overproduction of extracellular matrix and the resultant tissue fibrosis in SSc. Calpains are members of the Ca2+ -dependent cysteine protease family, whose enzymatic activities participate in signal transduction and tissue remodeling, potentially contributing to fibrosis in various organs...
August 25, 2023: Arthritis Research & Therapy
https://read.qxmd.com/read/37610259/effects-of-b-cell-depletion-by-cd19-targeted-car-t-cells-in-a-murine-model-of-systemic-sclerosis
#36
JOURNAL ARTICLE
Jérôme Avouac, Anne Cauvet, Cindy Orvain, Morgane Boulch, Françoise Tilotta, Ly Tu, Raphaël Thuillet, Mina Ottaviani, Christophe Guignabert, Philippe Bousso, Yannick Allanore
OBJECTIVE: To study the tolerance and efficacy of two B cell depletion strategies, including one with CD19-targeted chimeric antigen receptor (CAR) T cells, in a preclinical model mimicking the severe lung damages observed in systemic sclerosis (SSc). METHODS: B cell depletion strategies were evaluated in the Fra-2 transgenic (Tg) mouse model. We considered a first group of 16 untreated mice, a second group of 15 mice receiving a single dose of anti-CD20 monoclonal antibody (mAb) and a third group of 8 mice receiving CD19-targeted CAR-T cells in combination with anti-CD20 monoclonal antibody...
August 23, 2023: Arthritis & Rheumatology
https://read.qxmd.com/read/37587067/genome-wide-dna-methylation-and-transcriptome-expression-profiles-of-peripheral-blood-mononuclear-cells-in-patients-with-systemic-sclerosis-with-interstitial-lung-disease
#37
JOURNAL ARTICLE
Yanli Xie, Hongjun Zhao, Hui Luo, Xiaoxia Zuo, Quanzhen Li, Sijia Liu
OBJECTIVES: This study aims to investigate the genome-wide DNA methylation and transcriptome expression profiles of peripheral blood mononuclear cells (PBMCs) in patients with systemic sclerosis (SSc) with interstitial lung disease (ILD), and to analyze the effects of DNA methylation on Wnt/β-catenin and chemokine signaling pathways. METHODS: PBMCs were collected from 19 patients with SSc (SSc group) and 18 healthy persons (control group). Among SSc patients, there were 10 patients with ILD (SSc with ILD subgroup) and 9 patients without ILD (SSc without ILD subgroup)...
June 28, 2023: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://read.qxmd.com/read/37586673/clinical-correlates-of-a-subset-of-anti-fibroblast-antibodies-in-systemic-sclerosis
#38
JOURNAL ARTICLE
Elvira Favoino, Paola Cipriani, Vasiliki Liakouli, Addolorata Corrado, Luca Navarini, Marta Vomero, Adriana Sisto, Rosa Daniela Grembiale, Francesco Ciccia, Francesco P Cantatore, Piero Ruscitti, Roberto Giacomelli, Federico Perosa
Anti-fibroblast antibodies (AFA) have been reported in systemic sclerosis (SSc) and are known to promote fibroblast activation. Aim of this study was to characterize the fine specificity of AFA and to analyze any correlations with clinical parameters associated to fibrosis. To this end, AFA were affinity-purified from a patient with diffuse cutaneous SSc (dcSSc) and interstitial lung disease (ILD). Panning of a phage display peptide library with purified AFA identified the motif <KxywxQ>. The peptide p121, bearing the AFA-specific motif, was used in ELISA to screen sera from 186 SSc patients and 81 healthy donors...
August 14, 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://read.qxmd.com/read/37555717/the-role-of-ccl24-in-systemic-sclerosis
#39
REVIEW
Hilit Levy, Udi Gluschnaider, Alexandra Balbir-Gurman
Systemic sclerosis (SSc) is a chronic immune-mediated disease characterized by microangiopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. Though not fully understood, the pathogenesis of SSc is dominated by microvascular injury, endothelial dysregulation, and immune response that are thought to be associated with fibroblast activation and related fibrogenesis. Among the main clinical subsets, diffuse SSc (dSSc) is a progressive form with rapid and disseminated skin thickening accompanied by internal organ fibrosis and dysfunction...
July 31, 2023: Rambam Maimonides Medical Journal
https://read.qxmd.com/read/37534953/nailfold-videocapillaroscopy-patterns-in-systemic-sclerosis-implications-for-cutaneous-subsets-disease-features-and-prognostic-value-for-survival
#40
JOURNAL ARTICLE
Carles Tolosa-Vilella, Maria Del Mar Rodero-Roldán, Alfredo Guillen-Del-Castillo, Adela Marín-Ballvé, Rafael Boldova-Aguar, Begoña Marí-Alfonso, Carlos Feijoo-Massó, Dolores Colunga-Argüelles, Manuel Rubio-Rivas, Luis Trapiella-Martínez, Nerea Iniesta-Arandia, Eduardo Callejas-Moraga, Francisco J García-Hernández, Luis Sáez-Comet, Cristina González-Echávarri, Norberto Ortego-Centeno, Mayka Freire, Jose Antonio Vargas-Hitos, Juan J Ríos-Blanco, Jose Antonio Todolí-Parra, Ignasi Rodríguez-Pintó, Antonio-J Chamorro, Xavier Pla-Salas, Ana Belén Madroñero-Vuelta, Manuel Ruiz-Muñoz, Vicent Fonollosa-Pla, Carmen Pilar Simeón-Aznar
OBJECTIVES: To assess the associations and prognostic value of scleroderma patterns by nailfold videocapillaroscopy (NVC) in patients with systemic sclerosis (SSc) and cutaneous subsets. METHODS: At baseline, 1356 SSc patients from the RESCLE registry were compared according to the scleroderma pattern as Late pattern and non-Late pattern, which included Early and Active patterns. Patient characteristics, disease features, survival time and causes of death were analysed...
August 2023: Clinical and Experimental Rheumatology
keyword
keyword
41939
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.